JHS Svendgaard Laboratories Limited's Board of Directors, at its meeting held on June 25, 2026, approved a variation in the utilization of proceeds raised through a preferential issue, subject to shareholder approval. The decision modifies the objects previously sanctioned via postal ballot on June 23, 2025, which itself had amended the original approval accorded by shareholders at the Extra-Ordinary General Meeting held on July 04, 2024. The total estimated utilization amount remains unchanged at ₹2,999.99 lakh, with funds now redirected towards broader capital expenditure, business expansion, and strategic growth initiatives.

The Board cited evolving business requirements, manufacturing expansion plans, and long-term strategic objectives as the basis for the proposed modification. The revised structure consolidates the earlier allocation into three primary categories and extends the tentative timeline for utilization to March 31, 2027.

Existing vs. Revised Utilization Objects

The original utilization plan, as approved by shareholders on June 23, 2025, allocated funds for acquiring manufacturing equipment and infusing capital into group entities. The revised plan broadens these objectives to provide greater operational flexibility. The tables below outline both the existing and revised allocation structures.

Existing Objects (as approved on June 23, 2025):

*Considering 100% conversion of Warrants into Equity Shares within the stipulated time.

Objects After the Proposed Amendment:

*Considering 100% conversion of Warrants into Equity Shares within the stipulated time.

Key Objectives of the Amendment

Capital Expenditure and Business Expansion

Funds allocated under this head will be utilized for capital expenditure, infrastructure upgradation, resource sharing, and manufacturing and business development initiatives of the company. This category absorbs the previous allocation for equipment acquisition and expands the scope to include broader business development activities.

Strategic, Financial and Growth Initiatives

This category encompasses strategic investments, acquisitions, expansion initiatives, and restructuring activities aimed at meeting the company's growth objectives. The company may deploy these funds directly or through investments in group companies via loans, advances, inter-corporate deposits, equity, or other financial instruments, in compliance with applicable laws.

The Board noted that the proposed modification is primarily clarificatory in nature, intended to offer greater flexibility in the deployment of funds while continuing to achieve the same fundamental objectives for which the funds were originally raised. The variation is pursuant to the Companies Act, 2013, and relevant SEBI regulations concerning listing obligations and disclosure requirements. The Board meeting commenced at 04:11 P.M. and concluded at 04:33 P.M.

JHS Svendgaard Laboratories Limited narrowed its net loss to ₹192.24 lakh for the financial year ended March 31, 2026, from a loss of ₹1,974.43 lakh in the previous year. Revenue from operations for the year rose to ₹10,169.47 lakh, compared to ₹9,199.73 lakh in FY25, while total income stood at ₹10,514.34 lakh. The company's board of directors approved the audited standalone and consolidated financial results at a meeting held on May 26, 2026. The statutory auditors, M/s V.K. Khosla & Co., issued an unmodified opinion on the financial results.

Financial Performance

The company reported a basic and diluted earnings per share (EPS) of (₹0.22) for FY26, an improvement from (₹2.37) in the prior year. For the quarter ended March 31, 2026, the net loss was ₹356.56 lakh, with revenue from operations at ₹3,269.57 lakh. The board also took note of the Auditor’s Report issued by the statutory auditors. The paid-up equity share capital of the company stands at ₹8,740.58 lakh, comprising 8,74,05,767 equity shares of ₹10 each, following the conversion of warrants.

Operational and Capital Details

The company utilized funds raised through preferential allotment for projects in Jammu and Kashmir, general corporate purposes, and capital expenditure. Capital advances amounting to ₹3,252.75 lakh for facilities in Himachal Pradesh and ₹1,328.30 lakh for projects in Jammu & Kashmir were considered recoverable by the management. The auditors noted material weaknesses in internal financial controls over financial reporting, specifically regarding the reconciliation of trade receivables and payables, and the identification of non-moving inventory. The meeting was conducted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.